Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AKRX

Akorn (AKRX) Stock Price, News & Analysis

Akorn logo

About Akorn Stock (NASDAQ:AKRX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.09
$0.32
52-Week Range
N/A
Volume
1.19 million shs
Average Volume
9.60 million shs
Market Capitalization
$3.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Remove Ads
Receive AKRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter.

AKRX Stock News Headlines

Akorn Reaches New 52-Week High (AKRX)
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
See More Headlines

AKRX Stock Analysis - Frequently Asked Questions

Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings results on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.45. The business earned $204.69 million during the quarter, compared to analysts' expectations of $168.90 million. Akorn had a positive trailing twelve-month return on equity of 8.53% and a negative net margin of 55.64%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akorn investors own include Bristol-Myers Squibb (BMY), Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC) and Quantenna Communications (QTNA).

Company Calendar

Last Earnings
5/11/2020
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AKRX
CIK
3116
Fax
N/A
Employees
2,227
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-226,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$682.43 million
Price / Cash Flow
0.19
Book Value
$1.86 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$3.60 million
Optionable
Optionable
Beta
0.95
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AKRX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners